Rafael Holdings, Inc. (RFL) stock
Close on Nov 12, 2026Market cap $57.92MP/E –Yield –
Rafael Holdings, Inc. saw revenue fall 4.7% to $874.00K over the twelve months to Jul 31, 2026. Free cash flow was -$29.99M. At the latest close the market valued the company at $57.92M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 31, 2026
Valuation
- Market cap
- $57.92M
- P/E ratio
- –
- Price to sales
- 66.28
- Price to book
- 0.87
- Dividend yield
- –
- Free cash flow yield
- -51.77%
Fundamentals
- Revenue
- $874.00K
- Net income
- -$29.64M
- EPS, diluted
- -$0.58
- Free cash flow
- -$29.99M
- Book value per share
- $1.29
- Diluted shares
- 52M
Trading
- Next earnings
- Dec 10, 2026 (estimated, during market hours)
- Previous close
- $1.09
- Open
- $1.05
- Day's range
- $1.05 – $1.11
- Volume
- 27,502
- Average volume (20 days)
- 63,797
- Beta (5 years)
- 0.84
- 52-week range
- $0.99 – $3.96
- RSI (14 days)
- 37.2
- Volatility (1 year)
- 86.0%
- Relative volume
- 0.20×
- WACC
- 9.1%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | RFL | S&P 500 | Difference | RFL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -27.0% | -2.7% | −24.3 pts | ||
| 3 months | -43.9% | -1.7% | −42.2 pts | ||
| Year to date | -5.9% | +11.9% | −17.8 pts | ||
| 1 year | -12.6% | +12.0% | −24.6 pts | ||
| 3 years | -36.0% | +78.2% | −114.2 pts | -13.8% | +21.2% |
| 5 years | -83.5% | +73.2% | −156.8 pts | -30.3% | +11.6% |
| 10 years | -91.2% | +309.6% | −400.8 pts | -21.6% | +15.1% |
Twelve years at a glance
Fiscal years 2015 to 2026, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Rafael filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Update
- Results
About Rafael
Pharmaceutical Preparations
Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in early-stage and clinical healthcare and technology businesses. Its lead drug candidate, Trappsol Cyclo (remibetadex), targets Niemann-Pick Disease Type C. Through its subsidiaries and majority-owned portfolio entities, the company engages in liposomal cancer therapies via LipoMedix, orthopedic surgical instruments through Rafael Medical Devices, and product formulation technologies via Day Three Labs. It also retains legacy interests in cancer therapeutics and commercial real estate. Customers and commercial end users include healthcare providers, surgical specialists, diagnostic and pharmaceutical companies purchasing cyclodextrins, and third-party manufacturers utilizing proprietary ingredient technology.
Company profile, executives and historyRafael stock: common questions
What is Rafael's stock price?
RFL closed at $1.11 on Nov 12, 2026, up 1.83% on the day. Over the past 52 weeks it traded between $0.99 and $3.96.
What is Rafael's market cap?
Rafael was worth $57.92M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is RFL's P/E ratio?
Rafael lost money over the twelve months to Jul 31, 2026 (diluted EPS -$0.58), so it has no meaningful P/E ratio.
How much revenue does Rafael make?
Rafael reported revenue of $874.00K for the twelve months to Jul 31, 2026, down 4.7% from a year earlier.
Does Rafael pay a dividend?
No. Rafael has not paid a cash dividend over the last twelve months.
When does Rafael report earnings next?
Rafael is expected to report Q1 FY2027 results on Dec 10, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has RFL stock performed over the past year?
Including dividends, RFL returned -12.6% over the past year, against +12.0% for the S&P 500.
How many RFL shares are sold short?
0M shares were sold short at the latest FINRA report, 0.92% of the float, or 5.2 days of average trading volume.
Who are Rafael's competitors?
Companies most similar to Rafael by business, industry and size include SPRC, SPRB, XTLB, VCNX, LGVN.
See a number that looks wrong?